Shanghai Pharmaceuticals (SHA:601607, HKG:2607) has been authorized to market Pregabalin capsules in Thailand after its unit, SHP Thailand, received a drug registration certificate from the country's drug administration, according to a Shanghai bourse disclosure on Friday.
The drug is primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, and neuropathic pain associated with spinal cord injury, as well as an adjunctive treatment for epilepsy, the Chinese pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.